The Multicenter Prospective Randomized Controlled Trial Evaluating Efficacy of Dapagliflozin to Improve Long-Term Outcome of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure

The Multicenter Prospective Randomized Controlled Trial Evaluating Efficacy of Dapagliflozin to Improve Long-Term Outcome of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure - DARAF trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042603

Enrollment

200

Registered

2020-11-30

Start date

2021-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation in Patients with Heart Failure

Interventions

Patients are treated with Dapagliflozin for one year weeks following the catheter ablation Patients are treated without Dapagliflozin for one year weeks following the catheter ablation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Atrial fibrillation in patients with heart failure who undergo catheter ablation for atrial fibrillation. All patients are treated with oral anti-coagulants before the procedure.

Exclusion criteria

Exclusion criteria: Patients who are intolerant for SGLT-2 inhibitor Patients with renal insufficiency (estimated GFR < 30) When the attending physician consider inappropriate to enroll the patient in the study

Design outcomes

Primary

Measure	Time frame
Event free survival rate from atrial fibrillation and tachycardia following catherter ablation	—

Countries

Japan

Contacts

Public ContactKennosuke Yamashita

Showa University Northern Yokohama Hospital Department of Cardiovascular Medicine

kennosuke.atmm3@gmail.com045-949-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026